Shots: The approval is based on the P-III PEACHTREE trial to evaluate Xipere in 160 patients with macular edema associated with uveitis. The therapy is expected to be available in […]readmore
Tags : Bausch + Lomb
Shots: Bausch Health spin-off its leading eye health business into an independent publicly-traded company under the name Bausch + Lomb. The spinoff is expected to be completed in H1’21 The […]readmore
1.Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation Published: May 06, 2020 | Tags: Fitbit, Launches, Heart Study, Validate, Wearable Technology, Identifying, Atrial Fibrillation 2. […]readmore
Shots: STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of […]readmore
ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting […]readmore
Shots: The companies will collaboratively launch Bausch + Lomb Every Contact Counts recycling program in eyecare offices across Canada, allowing people to recycle their disposable contact lenses and blister pack […]readmore
Shots: Bausch + Lomb (Bausch Health’s subsidiary) acquires US commercial rights from Eton Pharmaceuticals for its EM-100, has been evaluated in P-III study vs PBO in patients with ocular itching […]readmore